LARGEST PHARMACEUTICAL COMPANY WORLDWIDE
2nd French laboratory,
2nd European laboratory in cardiology
treated every day across
the world by
including 5,000 in France
(Sept 30, 2019)
I have a very promising and confident view of our Group’s performance in an increasingly competitive world. We continue to develop our pipeline of research projects and drug candidates, while our sales growth remains strong.
We are inspired by our Vocation, driven by our Values and guided by our Vision. These are our pillars and our identity.
Around the world, the Servier Group’s 22,000 employees are committed to therapeutic progress to serve patient needs. Day after day, they work passionately to care for patients and save lives.
Launch a new
every three years
Become a key
player in the field of oncology while
maintaining our position
in cardiovascular health and diabetes
Reach a revenue
of €5 billion
Reach an operating
profit of 8% to
finance our development
Servier is at a pivotal moment in its transformation, and I am optimistic about its success. We have successfully rallied all employees around the same Vision and identified five strategic orientations.
During the year, the Group made new advances in the operational implementation of its five strategic orientations.
A focus on
The Servier Group is governed by a non-profit Foundation, the International Servier Research Foundation (Fondation Internationale de Recherche Servier – FIRS).
Unique in the pharmaceutical sector, the Group’s governance structure ensures its sustainability, preserves its independence and allows the reinvestment of all its profits into therapeutic progress and the development of its activities.
To ensure unity in strategy and day-to-day management, the same people serve on the executive committees of the FIRS Foundation and Servier SAS.
The results for the 2018/2019 financial year are in line with our expectations. Servier delivered a strong performance with an 11.1% growth in revenue at constant exchange rates. Business was driven by good…
Servier’s medicines are prescribed in 149 countries. The Group’s strategy of establishing local operations enables it to offer therapeutic solutions adapted to the specific characteristics of each country.
Our R&D model is constantly evolving to accelerate the delivery of medicines that respond to the real needs of patients. The establishment of the future Servier Paris‑Saclay Research Institute is a perfect illustration of our…
To discover new treatments that improve patients’ lives, Servier invests an average of 25% of its sales revenue (excl. generic medicines) in R&D. The Group focuses its research and development efforts in therapeutic areas where needs are substantial.
Every day, 100 million patients worldwide are treated with Servier medicines: medicines originating from its R&D in five therapeutic areas, quality generic medicines and e-health solutions via WeHealth™ Digital Medicine.
Learn more about our medications:
Given the changing face of our industry in terms of professions, we want all Group employees to have the means to succeed, to adapt, to take on responsibilities and to grow. At Servier, behavioral competencies like teamwork, adaptability, and respect are just as important as technical skills.
Servier’s Human Resources teams are committed to supporting the performance of the Group and its employees by offering each employee a unique and meaningful professional experience, the right skills, and an innovative organization.
Servier strives to provide objective, high-quality medical information to the health care community to ensure that its medicines are used safely. Medical Affairs plays a fundamental role as the guarantor of the objectivity and integrity of the information provided to medical experts and communities worldwide.
Medicines are not just another consumer product. They are subject to very strict regulations. As such, Servier has adopted responsible practices at each stage of the product chain to ensure the quality, efficacy, and safety of its products.
Since the appointment of a Chief Patient Officer in 2018, the patient approach has gained momentum within the Group. Servier works increasingly closely with patients to involve them in all stages of the medicine life cycle: from research and development to marketing and beyond.
Medical conditions vary from one continent to another. In order to respond to the diversity of health care needs, Servier relies on a broad geographic footprint that allows for close proximity to local therapeutic needs and an array of health care solutions adapted to the specific characteristics of each country.
Servier relies on the sharing of expertise in Research & Development to accelerate innovation and provide patients with solutions that are increasingly tailored to their needs. This cross-fertilization of ideas paves the way for research that’s more dynamic, agile, and open.
Despite significant advances in oncology in recent years, therapeutic needs remain considerable throughout the world. This is why fighting cancer is a strategic priority for Servier.
A guarantor of the quality and safety of medicines, Servier’s industrial model is part of a continuous improvement process aimed at achieving operational excellence. This approach serves the Group’s long-term strategic ambitions and responds to the trends shaping the sector.
Through four specialized subsidiaries, the Group offers a broad range of high-quality generic medicines. This steadily evolving activity increases the number of treatment options available to patients.
Servier strives to embrace a more responsible, virtuous, and sustainable economic model. This model reflects the Group’s desire to ensure that all of its actions are sustainable and serve future generations.